Valuation: Evotec SE

Market Cap 464M 516M 433M 392M 736M 49.07B 741M 5.19B 2.03B 25.47B 1.94B 1.89B 81.9B P/E 2026 *
-2.04x
P/E 2027 * -6.06x
Enterprise Value 606M 674M 566M 513M 963M 64.19B 969M 6.79B 2.65B 33.31B 2.53B 2.48B 107B EV / Sales 2026 *
1.01x
EV / Sales 2027 * 0.87x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day+6.71%
1 week-11.11%
Current month-15.87%
1 month-8.81%
3 months-30.45%
6 months-51.61%
Current year-52.15%
1 week 2.41
Extreme 2.406
2.9
1 month 2.41
Extreme 2.406
3.14
Current year 2.41
Extreme 2.406
6.73
1 year 2.41
Extreme 2.406
7.3
3 years 2.41
Extreme 2.406
21.69
5 years 2.41
Extreme 2.406
45.47
10 years 2.41
Extreme 2.406
45.83
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 58 2019-06-18
Director/Board Member 64 2021-05-31
Director/Board Member 59 2024-06-09
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/26 Exercice

Chief Technology Officer

12,462 0.0070%
5/4/26 Buy 15,510 0.0087%
5/4/26 Buy

Head of Human Resources

15,228 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+6.71%-11.11%-60.40%-84.71% 486M
-2.01%-7.86%+60.74%+70.97% 70.44B
+3.84%-11.02%+8.59%+57.43% 50.31B
+3.35%+1.42%+11.85%+40.01% 47.51B
+0.51%+1.51%+27.96%+31.43% 42.91B
+2.70%-3.66%+307.41%+547.01% 40.39B
+0.69%-3.44%+9.52%+96.59% 39.69B
+0.06%-2.02%+11.25%+43.27% 30.59B
+0.24%-7.99%+38.51%+1.59% 26.8B
-0.39%-6.92%-13.60%-14.40% 22.36B
Average +1.55%-5.71%+40.18%+78.92% 37.15B
Weighted average by Cap. +0.99%-4.90%+54.67%+102.47%

Financials

2026 *2027 *
Net sales 599M 666M 559M 506M 951M 63.38B 957M 6.71B 2.62B 32.9B 2.5B 2.45B 106B 721M 802M 673M 610M 1.15B 76.35B 1.15B 8.08B 3.15B 39.63B 3.01B 2.95B 127B
Net income -222M -247M -207M -188M -353M -23.5B -355M -2.49B -971M -12.19B -927M -907M -39.22B -48.25M -53.66M -45.03M -40.81M -76.62M -5.11B -77.1M -540M -211M -2.65B -201M -197M -8.52B
Net Debt 143M 159M 133M 121M 227M 15.12B 228M 1.6B 625M 7.85B 597M 584M 25.24B 162M 180M 151M 137M 258M 17.16B 259M 1.82B 709M 8.91B 677M 663M 28.65B
Projected Income Statement - Annual - Evotec SE
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
26-10-14 €2.608 +6.71% 2,356,377
26-10-13 €2.444 -0.65% 1,617,177
26-10-12 €2.460 -11.13% 4,251,059
26-10-09 €2.768 -1.35% 782,994
26-10-08 €2.806 -4.36% 1,181,049
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Evotec SE
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.608EUR
Average target price
4.443EUR
Spread / Average Target
+70.36%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evotec SE